Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
NCT ID: NCT00079612
Last Updated: 2014-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
501 participants
INTERVENTIONAL
2002-09-30
2007-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Find out if BAY 43-9006 prevents the growth of tumors
* For patients who have stable cancer status after 3 months of treatment if it is safer and/or more effective to continue to give BAY 43-9006 or to stop giving BAY 43-9006 at that time.
* Find out how long the effect of BAY 43-9006 is on tumors. To assess the safety of BAY 43-9006 (sorafenib) in the treatment of advanced refractory cancers.
* Measure the amount of BAY 43-9006 and some of its targets in the blood stream in some patients.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Sorafenib (Nexavar, BAY43-9006)
800mg daily (2x 400mg tabs)
Arm 2
Placebo
2x 400mg tabs daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sorafenib (Nexavar, BAY43-9006)
800mg daily (2x 400mg tabs)
Placebo
2x 400mg tabs daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with non-colorectal cancers are eligible and must be progressing at the time of the screening assessment and for whom no other treatment exists
* Patients with at least one (1) measurable tumor, per the WHO Tumor Response Criteria - Histological or cytological documentation of cancer- ECOG Performance status 0 or 1
* Life expectancy of at least 12 weeks- Adequate bone marrow, liver and renal function (assessed by the following laboratory requirements):
* Hemoglobin \>/= 9.0 g/dl - Absolute neutrophil count (ANC) \>/=1,500/mm3
* Platelet count = 100,000/µl3
* Total bilirubin \</=1.0 times the upper limit of normal unless due to Gilbert's
* ALT and AST \</= 2.5 x upper limit of normal. (For patients with hepatic involvement of their cancer, ALT and AST \< 5.0 x upper limit of normal)
* PT-INR/PTT \< 1.5 x upper limit of normal. (Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.
In addition, these patients must be monitored with weekly coagulation assessments throughout the Run-in Period)- Serum creatinine \< 1.5 x upper limit of normal
Exclusion Criteria
* Non small cell lung cancer, hepatocellular cancer, CML and AML
* Serious cardiac arrhythmia
* Congestive Heart Failure (NYHA Class 3 or 4)
* Active of coronary artery disease or ischemia
* Active acute infections that could be worsened by anticancer therapy or interfere with this study
* Known HIV infection
* Metastatic brain or meningeal tumors unless the patient is \> 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry
* Patients currently receiving medication (steroid or anticonvulsant therapy) for seizure disorder
* History of organ allograft- Previous or concurrent cancer that is distinct from the cancer being evaluated in this study. Several situations are excluded, including cervical carcinoma in situ, adequately treated basal cell carcinoma, superficial bladder tumors or any cancer definitively treated greater than 3 years
* Anticancer chemotherapy or immunotherapy during the study or within 4 weeks prior to the first dose of study drug
* Radiotherapy during the study or within 3 weeks prior to the first dose of study drug
* Bone marrow transplant or stem cell rescue within 4 months prior to the first dose of study drug
* Biological response modifiers, such as G-CSF within 3 weeks prior to study entry
* Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study
* Investigational drug therapy outside of this trial during or within 4 weeks prior to the screening assessment
* Any previous exposure to a Ras pathway inhibitor
* Pregnant or breast feeding patients. Women of child bearing potential must have a negative pregnancy test. Adequate barrier contraception will be required for both male and female patients during the entire course of the trial
* Substance abuse, medical or psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
* Known or suspected allergy to the investigational agent or any agent given in association with the trial
* Any condition that is unstable or could jeopardize the safety of the patient and/or their compliance in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chicago, Illinois, United States
Philadelphia, Pennsylvania, United States
Houston, Texas, United States
San Antonio, Texas, United States
London, Greater London, United Kingdom
Glasgow, Strathclyde, United Kingdom
Sutton, Surrey, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
100391
Identifier Type: -
Identifier Source: org_study_id
NCT00044499
Identifier Type: -
Identifier Source: nct_alias